Figure 6. PSCNPs induce anti-cancer immunity in bilateral tumor models.

a, A schematic illustration showing the experimental design. Bilateral tumor-bearing C3H mice (n = 5) were i.t. injected with one dose of saline or PSCNPs (27 mg/mL, 50 μL) in the primary tumor 14 days after tumor inoculation. The tumors, spleen, tumor-draining lymph nodes (TDLNs) and blood were collected on Day 3, 7, and 12 for flow cytometry analysis. b, Tumor growth curves for the secondary tumors. c-g, Flow cytometry analysis of leucocyte profiles in blood and tissue samples on Day 3, 7 and 12, including c) CD8⁺ T cells, d) CD8⁺IFN-γ⁺ T cells, e) CD4⁺Foxp3⁺ T cells (Tregs), f) CD8⁺ T cells/Treg ratio, and g) CD80⁺CD86⁺ DCs and CCR7⁺CD80⁺CD86⁺ DCs in the primary tumors (* p < 0.05).